视神经脊髓炎谱系疾病患者中利妥昔单抗的降阶梯治疗
基于法国NMOSD登记库(NOMADMUS)的病例系列,分析137例利妥昔单抗降阶梯治疗,主要结局为12个月时NMOSD再激活的绝对风险。AQP4+患者12个月内再激活风险为9.2%(95%CI 4.7-15.9),AQP4-患者为27.8%(95%CI 9.7-53.5)。作者结论认为无论何种降阶梯方案均存在NMOSD再激活风险。
要点
- 真实世界数据中利妥昔单抗降阶梯后12个月内AQP4+患者再激活风险9.2%,AQP4-患者27.8%。
- 除AQP4+患者妊娠相关降阶梯外,无其他降阶梯组在整个随访期间保持无复发。
- 作者结论认为无论何种利妥昔单抗降阶梯方案均存在NMOSD再激活风险。
核心结论
- 无论采用何种利妥昔单抗降阶梯方案,均存在NMOSD再激活风险。
研究设计与样本
- 法国NMOSD登记库(NOMADMUS)中利妥昔单抗降阶梯的真实世界病例系列。
- 纳入所有符合2015年国际NMO诊断小组(IPND)NMOSD诊断标准且降阶梯后随访至少12个月的患者。
- 通过计算机化筛查提取7种预定义降阶梯方案,排除因无效或原因不明而停用利妥昔单抗者。
- 共识别2006年至2019年间137例利妥昔单抗降阶梯。
- 主要结局为12个月时NMOSD再激活(一次或多次复发)的绝对风险,AQP4+与AQP4-血清型分别分析。
主要发现
- 7种降阶梯方案例数:单次输注后停药13例,单次输注后换用口服药6例,周期性输注后停药9例,周期性输注后换用口服药5例,妊娠前降阶梯4例,耐受性问题后降阶梯9例,延长输注间隔91例。
- 除AQP4+患者妊娠相关降阶梯外,无任何组在整个降阶梯随访期间(平均3.2年,范围0.79-9.5年)保持无复发。
- 12个月内所有组合计,AQP4+ NMOSD患者119例降阶梯中11例再激活(9.2%,95%CI 4.7-15.9),发生于0.69至10.0个月。
- 12个月内所有组合计,AQP4- NMOSD患者18例降阶梯中5例再激活(27.8%,95%CI 9.7-53.5),发生于1.1至9.9个月。
关键数值与推荐
- NMOSD诊断采用2015年国际NMO诊断小组(IPND)标准。
- 试验注册号:ClinicalTrials.gov NCT02850705。
- 证据等级:本研究提供IV级证据表明利妥昔单抗降阶梯增加疾病再激活概率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Exit strategies such as de-escalations have not been evaluated for rituximab in patients with neuromyelitis optica spectrum disorder (NMOSD). We hypothesized that they are associated with disease reactivations and aimed to estimate this risk. METHODS: We describe a case series of real-world de-escalations from the French NMOSD registry (NOMADMUS). All patients met the 2015 International Panel for NMO Diagnosis (IPND) diagnostic criteria for NMOSD. A computerized screening of the registry extracted patients with rituximab de-escalations and at least 12 months of subsequent follow-up. We searched for 7 de-escalation regimens: scheduled discontinuations or switches to an oral treatment after single infusion cycles, scheduled discontinuations or switches to an oral treatment after periodic infusions, de-escalations before pregnancies, de-escalations after tolerance issues, and increased infusion intervals. Rituximab discontinuations motivated by inefficacy or for unknown purposes were excluded. The primary outcome was the absolute risk of NMOSD reactivation (one or more relapses) at 12 months. AQP4+ and AQP4- serotypes were analyzed separately. RESULTS: We identified 137 rituximab de-escalations between 2006 and 2019 that corresponded to a predefined group: 13 discontinuations after a single infusion cycle, 6 switches to an oral treatment after a single infusion cycle, 9 discontinuations after periodic infusions, 5 switches to an oral treatment after periodic infusions, 4 de-escalations before pregnancies, 9 de-escalations after tolerance issues, and 91 increased infusion intervals. No group remained relapse-free over the whole de-escalation follow-up (mean: 3.2 years; range: 0.79-9.5), except pregnancies in AQP+ patients. In all groups combined and within 12 months, reactivations occurred after 11/119 de-escalations in patients with AQP4+ NMOSD (9.2%, 95% CI [4.7-15.9]), from 0.69 to 10.0 months, and in 5/18 de-escalations in patients with AQP4- NMOSD (27.8%, 95% CI [9.7-53.5]), from 1.1 to 9.9 months. DISCUSSION: There is a risk of NMOSD reactivation whatever the rituximab de-escalation regimen. TRIAL REGISTRATION INFORMATION: Registered on ClinicalTrials.gov: NCT02850705. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that de-escalation of rituximab increases the probability of disease reactivation.
引用
- Demuth S, Collongues N, Audoin B, et al. Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder. Neurology. 2023. PMID: 37290967. doi:10.1212/WNL.0000000000207443
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。